SCHEMBL1683379

SCHEMBL1683379

Cc1c(Cl)c(O)cc(Cc2ccc(Cl)cc2)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALOX15 P16050 3/20 0.45
CYP3A4 P08684 3/20 0.45
HPGD P15428 2/20 0.45
HIF1A Q16665 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 2/20 0.40
HSP90AA1 P07900 2/20 0.40
BCL2 P10415 1/20 0.40
BCL2L1 Q07817 1/20 0.40
SLC22A1 O15245 1/20 0.40
USP2 O75604 1/20 0.40
HSPD1 P10809 1/20 0.40
HSPA5 P11021 1/20 0.40
IDO1 P14902 1/20 0.40
ALOX12 P18054 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11785179 0.74 MEN1 (0.54) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL30024208 0.74 MEN1 (0.59) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL11311046 0.74 ALOX15 (0.41) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL27626950 0.72 HIF1A (0.79) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL11785185 0.71 BCL2 (0.56) MEN1KMT2AALOX15CYP3A4HPGD
SCHEMBL1683378 0.71 KMT2A (0.47) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL11260186 0.71 MEN1 (0.65) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL10982291 0.70 MAPT (0.50) MAPTMEN1KMT2AALOX15CYP3A4
SCHEMBL28623712 0.70 HPGD (0.46) MAPTALOX15CYP3A4HPGDHIF1A
SCHEMBL11685074 0.69 MEN1 (0.53) MAPTMEN1KMT2AALOX15CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086823-A1 DISINFECTANT BAYER ANIMAL HEALTH GMBH (DE) 2011-04-14 US claimed
US-20080221222-A1 Disinfectant BAYER HEALTHCARE LLC (DE) 2008-09-11 US claimed
EP-1909569-A2 DISINFECTING AGENT CONTAINING A COMBINATION OF BIOCIDAL PHENOLS AND A KERATOLYTIC Bayer HealthCare AG (DE) 2008-04-16 EP claimed
WO-2007009606-A2 DISINFECTING AGENT CONTAINING A COMBINATION OF BIOCIDAL PHENOLS AND A KERATOLYTIC BAYER HEALTHCARE AG (DE) 2007-01-25 WO claimed
EP-2310018-B1 USE OF NIFURTIMOX FOR TREATING GIARDIASIS BAYER IP GMBH (DE) 2013-12-18 EP disclosed
US-8440612-B2 Controlling giardiosis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-14 US disclosed
US-20110168623-A1 FEED SIDE PASSAGE MATERIAL AND SPIRAL SEPARATION MEMBRANE ELEMENT NITTO DENKO CORPORATION (JP) 2011-07-14 US disclosed
US-20110105388-A1 NOVEL POSSIBILITY OF CONTROLLING GIARDIOSIS BAYER ANIMAL HEALTH GMBH (DE) 2011-05-05 US disclosed
EP-2310018-A1 USE OF NIFURTIMOX FOR TREATING GIARDIASIS Bayer Animal Health GmbH (DE) 2011-04-20 EP disclosed
US-20110086823-A1 DISINFECTANT BAYER ANIMAL HEALTH GMBH (DE) 2011-04-14 US disclosed
WO-2010000399-A1 USE OF NIFURTIMOX FOR TREATING GIARDIASIS BAYER ANIMAL HEALTH GMBH (DE) 2010-01-07 WO disclosed
US-20080221222-A1 Disinfectant BAYER HEALTHCARE LLC (DE) 2008-09-11 US disclosed
EP-1909569-A2 DISINFECTING AGENT CONTAINING A COMBINATION OF BIOCIDAL PHENOLS AND A KERATOLYTIC Bayer HealthCare AG (DE) 2008-04-16 EP disclosed
WO-2007009606-A2 DISINFECTING AGENT CONTAINING A COMBINATION OF BIOCIDAL PHENOLS AND A KERATOLYTIC BAYER HEALTHCARE AG (DE) 2007-01-25 WO disclosed
EP-1380208-B1 Disinfectant agent with antiparasitic activity EWABO CHEMIKALIEN GMBH (DE) 2005-06-29 EP disclosed
EP-1380208-A1 Disinfectant agent with antiparasitic activity Ewabo Chemikalien GmbH (DE) 2004-01-14 EP disclosed
US-5620655-A MIXTURE OF A PHENOL COMPOUND AND ORGANIC ACID MENNO-CHEMIE-VERTRIEB GMBH (DE) 1997-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105388-A1 NOVEL POSSIBILITY OF CONTROLLING GIARDIOSIS TNNI3, PIGO, GLRX3 MAPT 4798/4885MEN1 2736/4885KMT2A 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.